Mechanism of Action of Sulfonamides
Sulfonamides inhibit bacterial dihydropteroate synthase (DHPS), a critical enzyme in the folic acid biosynthesis pathway, thereby preventing bacterial DNA synthesis and growth. 1, 2
Core Mechanism
Sulfonamides act as competitive inhibitors of dihydropteroate synthase, the enzyme responsible for incorporating para-aminobenzoic acid (PABA) into dihydropteroic acid during bacterial folate synthesis 2. This structural mimicry is key—sulfonamides closely resemble PABA, allowing them to compete for the same binding site on DHPS 2.
Why This Matters Clinically
The selectivity of sulfonamides stems from a fundamental difference between prokaryotes and eukaryotes:
- Bacteria must synthesize their own folic acid de novo and possess DHPS
- Mammalian cells obtain folic acid from dietary sources through uptake systems and generally lack DHPS 2
This explains why sulfonamides can selectively target bacteria without directly affecting human folate metabolism.
Downstream Effects
By blocking DHPS, sulfonamides interrupt the entire folate synthesis pathway 1. This cascade leads to:
- Depletion of tetrahydrofolate cofactors needed for one-carbon transfer reactions
- Impaired synthesis of purines and thymidine
- Inhibition of bacterial DNA replication and cell division
- Bacteriostatic effect (growth inhibition rather than direct killing) 3, 4
Resistance Mechanisms
Understanding resistance helps explain treatment failures 1, 2:
- Target site mutations: Clinical resistant strains develop mutations in the folP gene (encoding DHPS) that reduce sulfonamide binding while maintaining normal PABA substrate binding—a remarkable feat given the structural similarity between substrate and inhibitor 2
- Horizontal gene transfer: Gram-negative bacteria commonly acquire plasmid-borne resistance genes (sul1 and sul2) encoding alternative DHPS variants with pronounced insensitivity to sulfonamides 2
- Compensatory mutations: Unlike laboratory mutants that show reduced enzyme performance, clinical resistant strains have additional mutations allowing DHPS to function normally despite drug resistance 2
Clinical Implications
The mechanism explains several important clinical observations:
- Synergy with trimethoprim: Trimethoprim inhibits dihydrofolate reductase (the next enzyme in the folate pathway), creating sequential blockade that enhances antibacterial activity 1, 5
- Slow onset: As bacteriostatic agents, sulfonamides require time to deplete existing folate pools before growth inhibition becomes apparent 4
- Reading endpoints: In susceptibility testing, sulfonamides may show trailing endpoints with reduced growth rather than complete inhibition, making MIC determination challenging 6